Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of L
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
JPMorgan Removes Akero Therapeutics (AKRO) from Analyst Focus List and Catalyst Watch, PT $62
October 10, 2023 12:35 PM EDTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $62.00 price target on Akero Therapeutics (NASDAQ: AKRO).
The analyst comments "In our view, the totality of the SYMMETRY dataset continues to support EFX having a differentiated impact on histology across the spectrum of... More
Akero Therapeutics (AKRO) declines after efruxifermin NASH trial readout disappoints; Is it time to buy?
October 10, 2023 8:26 AM EDTShares Akero Therapeutics (NASDAQ: AKRO) declined after it reported analysis of data from its study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH). The stock declined as much as 60% shortly after the data release.
The drug missed its primary endpoint but efficacy trends were positive in a tough population, and the selloff in shares could be an overreaction, said analysts at Cantor Fitzgerald.
Canaccord Genuity analysts said they would be strong buyers... More
Canaccord on Akero Therapeutics (AKRO): 'We would be strong buyers on this weakness'
October 10, 2023 8:21 AM EDTCanaccord Genuity analyst Edward Nash reiterated a Buy rating and $59.00 price target on Akero Therapeutics (NASDAQ: AKRO)
The analyst comments "Akero Therapeutics reports 36-week analysis of SYMMETRY, a 96-week Phase IIb study evaluating the efficacy and safety of its lead product candidate efruxifermin... More
Cantor Fitzgerald on Akero Therapeutics (AKRO), 'we expect the stock to trade down'
October 10, 2023 7:55 AM EDTCantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and $69.00 price target on Akero Therapeutics (NASDAQ: AKRO)
The analyst comments "EFX efficacy meets our mixed scenario, and we expect the stock to trade down (premarket stock is trading down 50%+, which seems an... More
89bio Inc. (ETNB) Trades Lower in Sympathy with Akero Therapeutics (AKRO)
October 10, 2023 7:17 AM EDT89bio Inc. (NASDAQ: ETNB) Trades Lower in Sympathy with Akero Therapeutics (NASDAQ: AKRO)
Akero -63% Following NASH DataETNB -40%... MoreAkero Therapeutics (AKRO) Falls 48% Following 6-Week Analysis of 96-Week Phase 2b SYMMETRY Study for NASH
October 10, 2023 7:07 AM EDTAkero Therapeutics (NASDAQ: AKRO) Falls 48% Following 6-Week Analysis of 96-Week Phase 2b SYMMETRY Study for NASH
22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to... More